Christopher Wright, MD, PhD
Chief Medical Officer, Head of Translational Research
Chris Wright joined Ring as Chief Medical Officer, Head of Translational Research in February of 2023. Prior to joining Ring, Dr. Wright served as Chief Medical Officer of AavantiBio, Inc., a gene therapy company which was recently acquired by Solid Biosciences. Previously, Dr. Wright served as Chief Medical Officer at Cyclerion, and Senior Vice President/Chief Development Officer at Ironwood Pharmaceuticals. Before Ironwood, Dr. Wright held numerous executive positions at pharma companies including Axcella Health. Inc. and Vertex Pharmaceuticals. Prior to his industry roles, Dr. Wright was an Associate Professor of Neurology at Harvard Medical School and a board-certified practicing neurologist at Brigham and Women’s Hospital for 20 years. Dr. Wright earned an A.B. in biochemical sciences from Harvard University, an M.D. and MMSc. from Harvard Medical School and a Ph.D. in neurosciences from Vrije University in the Netherlands. He currently serves on the Board of Directors at Alkermes plc, and as Scientific Advisor at Cyclerion Therapeutics, Inc.